title: Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancer.
abstract: To reduce the morbidity and mortality from colorectal cancer (CRC), current clinical practice focuses on screening for early detection and polypectomy as a form of secondary prevention, complemented with surgical interventions when appropriate. No pharmaceutical agent is currently approved for use in clinical practice for the management of patients at risk for CRC. This article will review earlier attempts to develop pharmaceuticals for use in managing patients with a sporadic or genetic risk of CRC. It will also discuss therapeutic end points under evaluation in current efforts to develop drugs for treating CRC risk factors.
authors.affiliation: Department of Internal Medicine, The University of Arizona Medical Center, PO Box 245040, 1501 N Campbell Avenue, Tucson, AZ 85724, USA.
authors.forename: Nathaniel S
authors.initials: NS
authors.lastname: Rial
authors.forename: Jason A
authors.initials: JA
authors.lastname: Zell
authors.forename: Alfred M
authors.initials: AM
authors.lastname: Cohen
authors.forename: Eugene W
authors.initials: EW
authors.lastname: Gerner
mesh_terms: D011125:Adenomatous Polyposis Coli / Q000175:diagnosis; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018890:Chemoprevention; D002986:Clinical Trials as Topic; D003113:Colonoscopy; D015179:Colorectal Neoplasms / Q000209:etiology / Q000235:genetics / Q000517:prevention & control*; D003123:Colorectal Neoplasms, Hereditary Nonpolyposis / Q000175:diagnosis; D000518:Eflornithine / Q000627:therapeutic use; D020022:Genetic Predisposition to Disease; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000150:complications; D009364:Neoplasm Recurrence, Local; D013467:Sulindac / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D013467:Sulindac; D000518:Eflornithine